METASTATIC BREAST CANCER AS A CHRONIC DISEASE – CASE REPORT

Authors

  • Kosta Z. Zdravković Health Center Vranje, Serbia
  • Jelena Zdravković Health Center Vranje, Serbia
  • Marina Rašić-Popović Health Center Vranje, Serbia

Keywords:

metastatic breast cancer, chronic disease, CA 15-3

Abstract

Metastatic breast cancer could be diagnosed during follow-up after treatment of early breast cancer, during adjuvant therapy or after complete medical treatment and initially at the time of diagnosis of breast cancer, which is about in 10% of cases. A 44-year-old patient was diagnosed with primarily exulcerated breast cancer with skin infiltration, as well as metastases in regional axillary lymph nodes and distant metastases in the lungs and bones. Histological it is an invasive ductal breast cancer, immunohistochemically it was confirmed the presence of estrogen and progesterone receptors, with poor expression of human epidermal growth factor receptor 2 (HER2). The initial value of CA 15-3 was 164 U / ml. The patient was treated with palliative radiation therapy in the thoracic spine region, followed by chemotherapy FEC regimen FEC (5-fluorouracil, epirubicin, cyclophosphamide) with the maximum cumulative dose according to the protocol. After completition of chemotherapy, it was performed radiation therapy in breast and axilla region and it was initiated aromatase inhibitoe therapy. Progression-free survival (PFS) in this patient is currently 50 months and the value of tumor marker CA 15-3 is now in normal range.

Author Biographies

Kosta Z. Zdravković, Health Center Vranje, Serbia

Department of Oncology

Jelena Zdravković, Health Center Vranje, Serbia

Department of Laboratory Medicine

Marina Rašić-Popović, Health Center Vranje, Serbia

Department of Internal Medicine

References

American Society of Health-System Pharmacists (2021, June 14). Retrieved from https://www.drugs.com/monograph/docetaxel.html

Atanaskovic-Markovic, Z., Bjegovic, V., Jankovic, S., Kocev, N., Laaser, U., & Marinkovic, J. (2003). The burden of disease and injury in Serbia. Belgrade: Ministry of health of the Republic of Serbia.

Burzykowski, T., Buyse, M., Piccart-Gebhart, MJ., Sledge, G., Carmichael, J., & Lück, H.J. (2008). Evaluation od tumor response, disease control, progression-free survival, and time to progression as potential surrogate and points in metastatic breast cancer. J Clin Oncol. 26(12):1987-1992.

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., & Andre, F. (2018). 4th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC4). Ann Oncol. 29:1634–1657.

Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J. (2018). Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast. 39:131–138.

Cassol, L., Graudenz, MS., Zelmanowicz, A., Cancela, A., Werutsky, G., Rovere, RK., & Garicochea B. (2010). Basal-like immunophenotype markers and prognosis in early breast cancer. Tumori. 96: 966-970.

Cheang, S. K. ,& Chia, D. (2009). Tu et al., “Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF,” [Abstract] J Clin Oncol.27 Suppl 15: A-519.

Di Leo, A., Isola, J., & Piette, F. (2017). A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat. 107: 214.

Forouzanfar, MH., Foreman, KJ., Delossantos, AM., Lozano, R., Lopez, AD., & Murray, CJL. (2011). Breast and cervical cancer in 187 countries between 1980 and 2010:a systemic analysis. Lancet. 378:1461-1484.

Green, M.C., Buzdar, A.U., & Smith, T. (2005). Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeky. JCO. 23:5983-92

Haukka, J., Byrnes, G., Boniol, M., & Autier, P. (2011).Trends in breast cancer mortality in Sweden before and after implementation of mammography screening. PloS One 6:e22422.

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA Cancer J Clin. 61:69-90.

Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., & Takahashi, S. (2016). Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today. 46(7):821–826.

Perey, L., Hayes, D.F., & Maimonis, P. (1992). Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res. 52: 2563-2568.

Sasieni, P.D., Shelton, J., Ormiston-Smith, N., Thomson, C.S., & Silcocks, P.B. (2011). What is the lifetime risk of developing cancer:the effect of adjusting for multiple primaries.Br J Cancer. 105:460-465.

Siegal, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics CA Cancer J Clin. 62:10-29.

Sundquist, M., Brudin, L., & Tejler, G. (2017). Improved survival in metastatic breast cancer 1985–2016. Breast. 31:46–50.

Sharma, S. (2009). Tumor markers in clinical practice: General principles and guidelines. Indian J Med Paediatr Oncol. 30(1): 1-8.

Stieber, P., & Heinemann, V. (2008). Sinnvoller Einsatz von Tumormarkern. J Lab Med. 32 (5): 339-360.

Sinha S. (2021). Retrieved from https://www.drugs.com/xeloda.html

Shigematsu, H., Ozaki, S., Yasui, D., & Hirata, T. (2017). A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy. International Journal of Surgery Case Reports. 39:293-296.

Spitale, A., Mazzola, P., Soldini, D., Mazzucchelli, L., & Bordoni, A. (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. Apr.20(4):628-35.

Sørlie, T., Perou, C.M., & Tibshirani, R. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98(19): 10869–10874.

Youlden, D.R., Cramb, S.M., Dunn, N.A.M., Muller, J.M., Pyke, C.M., & Baade, P.D. (2012). The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiology. 36:237-248.

Downloads

Published

2022-03-30

How to Cite

Z. Zdravković, K., Zdravković, J., & Rašić-Popović, M. (2022). METASTATIC BREAST CANCER AS A CHRONIC DISEASE – CASE REPORT. KNOWLEDGE - International Journal , 51(4), 539–543. Retrieved from https://ikm.mk/ojs/index.php/kij/article/view/5093